Literature DB >> 6959127

Metabolism and mechanism of action of 5-fluorodeoxycytidine.

E M Newman, D V Santi.   

Abstract

5-Fluoro-2'-deoxycytidine (FdCyd) is a potent inhibitor of growth of tissue culture cells. The major cytotoxic event appears to be inhibition of thymidylate synthetase as evidenced by reversal of the cytotoxicity with thymidine but not deoxycytidine and by the effect of FdCyd on nucleotide pools, which is characteristic of specific inhibition of this enzyme. The metabolism of FdCyd was established by using a method in which its cytotoxicity was compared in several S-49 mutant cell lines having defined single or double deficiencies of enzymes involved in nucleoside and nucleotide metabolism. Our results indicate that FdCyd is metabolized to 5-fluoro-2'-deoxyuridylate, a potent inhibitor of thymidylate synthetase by two pathways: (i) sequential reactions catalyzed by deoxycytidine kinase and deoxycytidylate deaminase and (ii) sequential reactions catalyzed by cytidine deaminase and thymidine kinase. We have shown that metabolism of FdCyd can be directed through the former pathway by inhibition of cytidine deaminase with tetrahydrouridine. Since cytidine deaminase appears to be responsible for catabolism of FdCyd in animals, our results suggest that the antineoplastic effects of FdCyd should be examined in combination with inhibitors of cytidine deaminase.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6959127      PMCID: PMC347137          DOI: 10.1073/pnas.79.21.6419

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  21 in total

1.  Mechanism of growth inhibition of H.Ep. 1 cells by 5-fluorodeoxycytidine and 5-fluorodeoxyuridine.

Authors:  L CHEONG; M A RICH; M L EIDINOFF
Journal:  Cancer Res       Date:  1960-12       Impact factor: 12.701

2.  Alternative pathways of thymine and uracil metabolism in the liver and hepatoma.

Authors:  C H DE VERDIER; V R POTTER
Journal:  J Natl Cancer Inst       Date:  1960-01       Impact factor: 13.506

3.  Assay of intracellular free and macromolecular-bound metabolites of 5-fluorodeoxyuridine and 5-fluorouracil.

Authors:  W L Washtien; D V Santi
Journal:  Cancer Res       Date:  1979-09       Impact factor: 12.701

4.  Allosteric regulation of calf thymus ribonucleoside diphosphate reductase.

Authors:  S Eriksson; L Thelander; M Akerman
Journal:  Biochemistry       Date:  1979-07-10       Impact factor: 3.162

5.  The effect of inhibition of cytidine deaminase by tetrahydrouridine on the utilization of deoxycytidine and 5-bromodeoxycytidine for deoxyribonucleic acid synthesis.

Authors:  G M Cooper; S Greer
Journal:  Mol Pharmacol       Date:  1973-11       Impact factor: 4.436

6.  A rapid and sensitive high pressure liquid chromatography assay for deoxyribonucleoside triphosphates in cell extracts.

Authors:  C Garrett; D V Santi
Journal:  Anal Biochem       Date:  1979-11-01       Impact factor: 3.365

Review 7.  Perspective on the design and biochemical pharmacology of inhibitors of thymidylate synthetase.

Authors:  D V Santi
Journal:  J Med Chem       Date:  1980-02       Impact factor: 7.446

8.  Effects of nucleoside triphosphates on human ribonucleotide reductase from Molt-4F cells.

Authors:  C H Chang; Y C Cheng
Journal:  Cancer Res       Date:  1979-12       Impact factor: 12.701

9.  The significance of the substrate specificity of T2r+-induced deoxycytidylate deaminase.

Authors:  G F Maley; F Maley
Journal:  J Biol Chem       Date:  1966-05-10       Impact factor: 5.157

10.  Mutator phenotypes in mammalian cell mutants with distinct biochemical defects and abnormal deoxyribonucleoside triphosphate pools.

Authors:  G Weinberg; B Ullman; D W Martin
Journal:  Proc Natl Acad Sci U S A       Date:  1981-04       Impact factor: 11.205

View more
  8 in total

Review 1.  DNA methylation: its role in cancer development and therapy.

Authors:  Carla Kurkjian; Shivaani Kummar; Anthony J Murgo
Journal:  Curr Probl Cancer       Date:  2008 Sep-Oct       Impact factor: 3.187

2.  Thymidylate synthetase inhibitors and fragile site expression in lymphocytes.

Authors:  P B Jacky; G R Sutherland
Journal:  Am J Hum Genet       Date:  1983-11       Impact factor: 11.025

Review 3.  Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer.

Authors:  William B Parker
Journal:  Chem Rev       Date:  2009-07       Impact factor: 60.622

4.  Biodistribution, Tumor Detection, and Radiation Dosimetry of 18F-5-Fluoro-2'-Deoxycytidine with Tetrahydrouridine in Solid Tumors.

Authors:  Colin R Young; Stephen Adler; Janet F Eary; M Liza Lindenberg; Paula M Jacobs; Jerry Collins; Shivaani Kummar; Karen A Kurdziel; Peter L Choyke; Esther Mena
Journal:  J Nucl Med       Date:  2018-11-02       Impact factor: 10.057

5.  A novel fluorescence-based assay for the rapid detection and quantification of cellular deoxyribonucleoside triphosphates.

Authors:  Peter M Wilson; Melissa J Labonte; Jared Russell; Stan Louie; Andrew A Ghobrial; Robert D Ladner
Journal:  Nucleic Acids Res       Date:  2011-05-16       Impact factor: 16.971

Review 6.  5-Aza-4'-thio-2'-deoxycytidine, a New Orally Bioavailable Nontoxic "Best-in-Class": DNA Methyltransferase 1-Depleting Agent in Clinical Development.

Authors:  William B Parker; Jaideep V Thottassery
Journal:  J Pharmacol Exp Ther       Date:  2021-09-09       Impact factor: 4.402

7.  Preclinical studies of 5-fluoro-2'-deoxycytidine and tetrahydrouridine in pediatric brain tumors.

Authors:  Marie Morfouace; Birgit Nimmervoll; Nidal Boulos; Yogesh T Patel; Anang Shelat; Burgess B Freeman; Giles W Robinson; Karen Wright; Amar Gajjar; Clinton F Stewart; Richard J Gilbertson; Martine F Roussel
Journal:  J Neurooncol       Date:  2015-10-30       Impact factor: 4.130

8.  Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells.

Authors:  V J Chen; J R Bewley; S L Andis; R M Schultz; P W Iversen; C Shih; L G Mendelsohn; D E Seitz; J L Tonkinson
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.